Chemomab Therapeutics Ltd DRC (CMMB)
$2.71
$-0.12
(-4.24%)
As on 04-Sep-2026 16:19EDT
Market cap
$20 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1
-
Face value
--
-
Shares outstanding
7,327,660
7 Years Aggregate
CFO
$-95.31 Mln
EBITDA
$-42.08 Mln
Net Profit
$-40.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
| 64.2 | 67.3 | 57.6 | -10.3 | -15.9 | -45.9 | -- |
|
BSE Sensex*
| -10.7 | -3.7 | 1.8 | -6.4 | 4.5 | 5.3 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
| -77.2 | 251.3 | -84.1 | -53.6 | -75.1 | 23.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
2.7 | 19.9 | 0.0 | -7.6 | -- | -72.3 | -- | 2.3 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Chemomab Therapeutics Ltd DRC (CMMB)
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal... antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel. Read more
-
Co-Founder, Chief Scientific Officer, CEO & Executive Director
Dr. Adi Mor George Ph.D.
-
Co-Founder, Chief Scientific Officer, CEO & Executive Director
Dr. Adi Mor George Ph.D.
-
Headquarters
Tel Aviv-Yafo
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Chemomab Therapeutics Ltd DRC (CMMB)
What is the current share price of Chemomab Therapeutics Ltd DRC (CMMB) Today?
The share price of Chemomab Therapeutics Ltd DRC (CMMB) is $2.71 (NASDAQ) as of 04-Sep-2026 16:19 EDT. Chemomab Therapeutics Ltd DRC (CMMB) has given a return of -15.92% in the last 3 years.
What is the current PB & PE ratio of Chemomab Therapeutics Ltd DRC (CMMB)?
Since, TTM earnings of Chemomab Therapeutics Ltd DRC (CMMB) is negative, P/E ratio is not available.
The P/B ratio of Chemomab Therapeutics Ltd DRC (CMMB) is 2.30 times as on 04-Sep-2026, a 57 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.43 |
1.05 |
2024 |
-2.45 |
2.52 |
2023 |
-0.07 |
0.10 |
2022 |
-0.34 |
0.26 |
2021 |
-1.58 |
0.32 |
What is the 52 Week High and Low of Chemomab Therapeutics Ltd DRC (CMMB)?
The 52-week high and low of Chemomab Therapeutics Ltd DRC (CMMB) are Rs 3.58 and Rs 1.35 as of 08-Sep-2026.
What is the market cap of Chemomab Therapeutics Ltd DRC (CMMB)?
Chemomab Therapeutics Ltd DRC (CMMB) has a market capitalisation of $ 20 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Chemomab Therapeutics Ltd DRC (CMMB)?
Before investing in Chemomab Therapeutics Ltd DRC (CMMB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.